Global clinical trials promise broader access, greater diversity, and faster enrollment. The ideal behind this ambition is that innovation should not be limited by borders. But beneath the promise of scale lies a quieter force that shapes enrollment outcomes: standard of care.
When trials expand across borders, they don’t just encounter new geographies. They encounter different treatment norms, diagnostic pathways, reimbursement realities, healthcare accessibility, and help-seeking behaviors.
For example:
- In oncology, uptake of newly approved therapies can vary by 2–5 years between the U.S. and certain EU or APAC markets due to reimbursement and regulatory lag (IQVIA Global Oncology Trends reports).
- Multinational registry analyses published in The Lancet Oncology show that treatment sequencing differs significantly across countries within the same cancer type — directly affecting line-of-therapy eligibility.
- A review in Trials found that overly restrictive eligibility criteria can exclude up to 75% of real-world patients, and this exclusion varies by region depending on care patterns.
These differences matter because eligibility criteria are often tied to prior treatments, diagnostic timing, or disease progression milestones. A protocol may be standardized. But the care patients receive before they encounter that protocol is not.
When patients exist — but aren’t diagnosed
Variation isn’t limited to treatment access. It also includes awareness and diagnosis.
A recent cross-sectional observational study, Real-World Evidence Shows Gaps in Awareness, Medical Help-Seeking, and Diagnosis for Primary Dysmenorrhea but Not Premenstrual Syndrome (JMIR 2025; e68148), demonstrated how dramatically care pathways can obscure patient populations.
In a survey of 3,546 women experiencing menstrual pain:
- 94.6% reported symptoms consistent with dysmenorrhea
- Yet only 4.6% reported receiving a formal diagnosis
- Approximately 90.3% either did not seek medical care, were unsure of their diagnosis, or were not recognized as having a pathological condition
- Nearly half of diagnosed participants were misclassified as having PMS
The conclusion is clear – large patient populations can exist outside formal healthcare recognition.
From a recruitment perspective, those patients are invisible to site databases, EHR queries, and physician referral networks. If recruitment strategy assumes diagnosis equals prevalence, enrollment projections will be fundamentally flawed.
The recruitment consequences
When standards of care differ globally, recruitment efficiencies can be affected in predictable ways:
Feasibility overestimation
Epidemiology may suggest large addressable populations. But if patients are diagnosed later, treated differently, or misclassified, the eligible pool shrinks dramatically.
Access, cost, and availability
Factors such as wait times, out-of-pocket costs, and access to available treatments significantly influence healthcare coverage and patient behavior. In regions where patients have easy access to medical professionals, minimal out-of-pocket expenses, and a broad range of approved therapies, interest in clinical trial participation may be lower. When standard care is accessible and effective, trials can feel optional.
Conversely, in markets where patients face long wait times, high personal healthcare costs, or limited treatment options, clinical trials may represent a valuable opportunity. Access to investigational therapies, specialized care, and reduced financial burden can make participation more appealing.
Personal and social situation
A patient’s willingness to participate in a clinical trial is not shaped by medical eligibility alone. It’s shaped by their personal and social reality — and that reality is deeply influenced by local standards of care. Factors such as financial stability, employment flexibility, caregiving responsibilities, family support, health literacy, cultural beliefs and trust, disease severity, emotional state, transportation, and perceived benefit v. risk.
Line-of-therapy mismatch
If a trial requires patients in second-line therapy but a region typically moves to biologics earlier — or later — eligibility windows shift.
The result: projected high-performing regions under-enroll.
Diagnostic gaps
As demonstrated in the dysmenorrhea study mentioned above, up to 90% of symptomatic individuals may never enter formal care pathways. If identification depends on healthcare system touchpoints, large segments of the population remain unreachable.
Regional enrollment variability
Countries may appear to have lower disease prevalence when, in reality, they have lower diagnosis rates. Others may show a high documented burden due to systematic screening. Without incorporating standards-of-care data, geographic allocation decisions risk being based on administrative visibility rather than real-world accessibility.
Why standards of care data is a recruitment imperative
Epidemiology tells you how many people have a condition. Standards of care data tells you:
- When they are diagnosed
- How they are treated
- Whether they progress through required therapy lines
- If they are visible to physicians
- Whether they are reachable through traditional channels
That distinction determines whether recruitment strategy is reactive or predictive The local healthcare system’s strengths and shortcomings — including wait times for specialist appointments, out-of-pocket expenditures, and available therapies—will influence the general baseline openness to clinical trials as an alternative treatment pathway to the standard processes of the local healthcare system. While health situations, personal needs, indication severity and prognosis, and personal perception are major drivers of interest in clinical trial participation, the local standard of care will affect the overall trend toward increased or more modest interest in clinical research.
The dysmenorrhea study further demonstrated that direct-to-patient digital outreach successfully engaged symptomatic individuals who were undiagnosed and outside traditional care — reinforcing that alternative engagement models can surface invisible patients.
In global trials, this insight becomes even more critical. Because when standards of care differ, visibility differs. When visibility differs, enrollment curves diverge.
SubjectWell designs recruitment around patient reality
Understanding standards of care is only powerful if it informs action. SubjectWell’s approach is built around bridging the gap between eligibility and accessibility.
Instead of relying solely patient databases or diagnosed populations, SubjectWell:
- Anticipates the standard-of-care and treatment landscape per country to make informed decisions
- Engages patients directly based on symptoms and real-world behavior
- Uses analytics and real-world data to prioritize those most likely to qualify
- Aligns outreach with local treatment patterns
- Delivers pre-screened, high-intent referrals to sites
- Supports patients in over 60 languages through Patient Companions
This model reduces dependence on diagnosis of visibility and physician referral variability — two of the largest friction points in global recruitment.
When standards of care vary, SubjectWell adapts the targeting strategy accordingly. The result is greater predictability, reduced screening burden, and improved time to First Patient In — even in complex multinational trials.
Global scale requires local reality
Global trials don’t struggle because patients aren’t out there. They struggle because the realities of how patients are diagnosed, treated, and moved through care systems may not benefit clinical trial patient recruitment. Standards of care affect the society’s (and thereby the individual’s) base interest in clinical trials as an alternative treatment pathway or healthcare access option — long before a protocol is introduced. Personal circumstances, indication severity and subjective experiences will then reinforce the individual’s mindset when it comes to clinical research and explanatory treatments. When recruitment strategies ignore those realities, projections falter and enrollment curves diverge. But when sponsors ground their approach in real-world treatment patterns and align outreach with how patients actually experience care, global complexity becomes manageable. In multinational research, success isn’t just about expanding geography — it’s about aligning protocol design with patient reality.
